Century Therapeutics Inc (IPSC)vsMerck & Company Inc (MRK)
IPSC
Century Therapeutics Inc
$2.20
0.00%
HEALTHCARE · Cap: $396.78M
MRK
Merck & Company Inc
$110.95
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 59454% more annual revenue ($65.01B vs $109.16M). MRK leads profitability with a 28.1% profit margin vs -8.8%. MRK earns a higher WallStSmart Score of 59/100 (C).
IPSC
Avoid27
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IPSC.
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$110.95
$14.47 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -6.0% — below average capital efficiency
Revenue declined 100.0%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IPSC
The strongest argument for IPSC centers on Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : IPSC
The primary concerns for IPSC are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
IPSC profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
IPSC carries more volatility with a beta of 1.67 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 27/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Century Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Century Therapeutics Inc. (Ticker: IPSC) is an innovative biotechnology firm at the forefront of advancing allogenic cell therapies aimed at transforming cancer treatment. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, the company is committed to developing novel off-the-shelf therapeutic solutions that enhance patient outcomes and broaden accessibility. With a robust pipeline of clinical-stage product candidates and strategic partnerships that bolster its competitive edge, Century Therapeutics is strategically positioned to lead advancements in the burgeoning cell therapy market, offering strong potential for clinical successes and favorable returns for investors.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?